Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Open Label, Follow up Study to Investigate the Long Term Tolerability and Safety of Oral BIBF 1120 on Top of Pirfenidone in Japanese Patients With Idiopathic Pulmonary Fibrosis

Next Previous
Trial Profile

A Phase II Open Label, Follow up Study to Investigate the Long Term Tolerability and Safety of Oral BIBF 1120 on Top of Pirfenidone in Japanese Patients With Idiopathic Pulmonary Fibrosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nintedanib (Primary) ; Pirfenidone
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 01 Dec 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
  • 03 Sep 2014 Planned End Date changed from 1 May 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
  • 03 Sep 2014 Planned primary completion date changed from 1 May 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top